Moreover, some patients have some complications, such as spine unstable fractures, severe lung damage disease, and contralateral lower extremity fractures, who are not suitable for the lateral decubitus position.5. ConclusionThe present results showed that PFNA with the lateral decubitus position and the supine position provided effective methods for the treatments of intertrochanteric fractures in the elderly patients. However, the PFNA with the lateral decubitus position provides a shorter operation time, less of hospital stay, blood loss, number of intraoperative X-ray, incision length and out-of-bed activity time. Therefore, PFNA fixation in the lateral decubitus position may be considered a better choice for the treatment of intertrochanteric fractures in the elderly patients. Although PFNA fixation in the lateral decubitus position was shown to be of value as the treatment of intertrochanteric fractures, further definitive research about early surgery and longer follow-up period is needed to support the use of PFNA fixation in the lateral decubitus position.Conflict of InterestsThere is no conflict of interests to declare, and all authors certify that they have no commercial associations that might pose a conflict of interests in connection with this paper.
Colorectal cancer is the third most common cancer and ranks as the fourth most common cancer-related mortality [1]. A major component of treatment failure is cancer dissemination within the abdominal and pelvic spaces as a local recurrence of the primary cancer or as peritoneal carcinomatosis (PC). It is estimated that about 40% of the patients with colorectal cancer will develop PC during the evolution of the disease [2] as a result of the growth of the primary tumor through the serosal lining of the bowel lumen, thereby allowing the exfoliation and shedding of malignant cells intraperitoneally. Manipulation during the surgical procedure may also release tumor cells within the peritoneal cavity [2].PC from colorectal cancer was traditionally regarded as a terminal condition. The terminal nature of this disease has been demonstrated in a large clinical trial, the French multicentric EVOCAPE-1 trial, which prospectively followed up 370 patients with PC of different primary cancers from diagnosis till death. The mean survival of 118 patients with PC from colorectal cancer was 6.0 months [3].For over two decades, adjuvant intravenous (IV) therapy with 5-fluorouracil (5-FU) has improved the therapeutic outcome after cytoreduction [4]. After the introduction of oxaliplatin in combination with 5-FU or leucovorin, the effectiveness of systemic treatment of PC was improved [5, 6].